Lost brain cells create lasting glitches in neural networks

Summary

During brain development, specialized cells called cortical inhibitory neurons must travel long distances to reach their final destinations. These neurons act as the essential braking system of the brain, keeping electrical signals balanced in regions like the neocortex, which handles complex thinking. Scientists have known that when this migration process is disturbed, it is linked to neuropsychiatric conditions. However, the exact way these temporary travel delays cause permanent functional glitches has remained a mystery.

To understand this process, researchers studied an animal model with a specific genetic tweak called a Cxcr4 knockout, mimicking a feature found in genetic schizophrenia models. They observed what happens when these inhibitory neurons lose their migratory guidance. The cells failed to populate a specific developmental area called the neocortical marginal zone. While the outer brain eventually received the right total number of these cells by birth, deeper emotional centers known as limbic regions suffered a permanent shortage of inhibitory neurons.

Surprisingly, the brain managed to fix the physical misplacement of these cells in the neocortex as it matured, with the physical layers eventually looking normal. Yet the early wandering took a hidden toll on the developing brain network. The misplaced cells developed altered molecular identities, formed different synaptic connections, and showed abnormal spontaneous activity early on. Because of this rocky start, the mature brain retained permanent functional anomalies, such as an abnormally facilitated spread of sensory signals across different brain areas.

Why it matters.

This research provides a crucial missing link between early developmental disruptions and lifelong psychiatric conditions. By revealing that the journey of a developing brain cell is just as important as its final destination, scientists now have a better understanding of how vulnerable the growing brain is to genetic and environmental stress. The finding that the brain can physically repair its cellular layers while retaining hidden electrical flaws could shift how researchers look for the origins of neuropsychiatric disorders. Instead of solely looking for structurally missing or misplaced cells, future diagnostics might need to focus on subtle changes in how sensory information is processed and propagated.

It is important to note that these findings are currently based on an early-stage animal model. While the genetic modification used mirrors aspects of human psychiatric diseases, further research is required to confirm if these exact mechanisms translate to human brains. Confirming these pathways in humans will be an essential next step before this knowledge can be used to develop targeted therapies or interventions for neuropsychiatric conditions.

From the source

The story in numbers.

Gene target for conditional knockout model: Cxcr4
Deficit duration for CIN numbers in limbic regions: Permanent

Keep the context

Follow the evidence.

This source is a preprint and has not completed peer review. Its findings are provisional.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

Lost brain cells create lasting glitches in neural networks

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.